Literature DB >> 3047672

KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas.

V T Smit1, A J Boot, A M Smits, G J Fleuren, C J Cornelisse, J L Bos.   

Abstract

DNAs from human pancreatic adenocarcinomas were analyzed for the presence of mutations in codons 12, 13 and 61 of the NRAS, KRAS and HRAS gene. Formalin-fixed and paraffin-embedded tissue was used directly in an in vitro amplification reaction to expand the relevant RAS sequences. The mutations were detected by selective hybridization using mutation-specific synthetic oligonucleotides. In 28 of the 30 patients we found a mutation in codon 12 of the KRAS gene. This result confirms the findings of Almoguera et al. [Cell 53 (1988) 549-554] that KRAS mutations occur frequently in adenocarcinomas of the exocrine pancreas. The mutations are predominantly G-T transversions, in contrast to the KRAS mutations in colon tumors which are mainly G-A transitions. Furthermore, in a portion of the tumors the mutation appears to be homozygous.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3047672      PMCID: PMC338489          DOI: 10.1093/nar/16.16.7773

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  20 in total

1.  Detection of high incidence of K-ras oncogenes during human colon tumorigenesis.

Authors:  K Forrester; C Almoguera; K Han; W E Grizzle; M Perucho
Journal:  Nature       Date:  1987 May 28-Jun 3       Impact factor: 49.962

Review 2.  Mutational activation of oncogenes in animal model systems of carcinogenesis.

Authors:  I Guerrero; A Pellicer
Journal:  Mutat Res       Date:  1987-05       Impact factor: 2.433

3.  Prevalence of ras gene mutations in human colorectal cancers.

Authors:  J L Bos; E R Fearon; S R Hamilton; M Verlaan-de Vries; J H van Boom; A J van der Eb; B Vogelstein
Journal:  Nature       Date:  1987 May 28-Jun 3       Impact factor: 49.962

4.  Guanosine triphosphatase activating protein (GAP) interacts with the p21 ras effector binding domain.

Authors:  H Adari; D R Lowy; B M Willumsen; C J Der; F McCormick
Journal:  Science       Date:  1988-04-22       Impact factor: 47.728

5.  Activated N-ras controls the transformed phenotype of HT1080 human fibrosarcoma cells.

Authors:  H Paterson; B Reeves; R Brown; A Hall; M Furth; J Bos; P Jones; C Marshall
Journal:  Cell       Date:  1987-12-04       Impact factor: 41.582

6.  Pancreatic neoplasia induced by ras expression in acinar cells of transgenic mice.

Authors:  C J Quaife; C A Pinkert; D M Ornitz; R D Palmiter; R L Brinster
Journal:  Cell       Date:  1987-03-27       Impact factor: 41.582

7.  Analysis of RAS gene mutations in acute myeloid leukemia by polymerase chain reaction and oligonucleotide probes.

Authors:  C J Farr; R K Saiki; H A Erlich; F McCormick; C J Marshall
Journal:  Proc Natl Acad Sci U S A       Date:  1988-03       Impact factor: 11.205

8.  A dot-blot screening procedure for mutated ras oncogenes using synthetic oligodeoxynucleotides.

Authors:  M Verlaan-de Vries; M E Bogaard; H van den Elst; J H van Boom; A J van der Eb; J L Bos
Journal:  Gene       Date:  1986       Impact factor: 3.688

9.  The cytoplasmic protein GAP is implicated as the target for regulation by the ras gene product.

Authors:  C Calés; J F Hancock; C J Marshall; A Hall
Journal:  Nature       Date:  1988-04-07       Impact factor: 49.962

10.  Detection of human papilloma virus in paraffin-embedded tissue using the polymerase chain reaction.

Authors:  D K Shibata; N Arnheim; W J Martin
Journal:  J Exp Med       Date:  1988-01-01       Impact factor: 14.307

View more
  193 in total

1.  Detection of k-ras gene point mutation in fine needle aspiration and pancreatic juice by sequence special primer method and its clinical significance.

Authors:  Xun-Liang Liu; Cun-Cai Dai; Yi Miao; Jing-Hui Du; Zhao-Song Zhang; Shu-Zhen Chen
Journal:  World J Gastroenterol       Date:  2000-12       Impact factor: 5.742

2.  Selective 'stencil'-aided pre-PCR cleavage of wild-type sequences as a novel approach to detection of mutant K-RAS.

Authors:  A V Lichtenstein; O I Serdjuk; T I Sukhova; H S Melkonyan; S R Umansky
Journal:  Nucleic Acids Res       Date:  2001-09-01       Impact factor: 16.971

3.  Pancreatic cancer and hedgehog pathway signaling: new insights.

Authors:  Joseph S Dosch; Marina Pasca di Magliano; Diane M Simeone
Journal:  Pancreatology       Date:  2010-05-07       Impact factor: 3.996

4.  Restriction endonuclease-catalyzed cleavage of DNA stimulates subsequent polymerase chain reaction and enables discrimination between normal and mutant K-RAS alleles.

Authors:  I V Botezatu; O I Serdyuk; G I Potapova; V P Shelepov; A V Likhtenshtein
Journal:  Dokl Biochem Biophys       Date:  2003 Nov-Dec       Impact factor: 0.788

Review 5.  Liquid biopsy in patients with pancreatic cancer: Circulating tumor cells and cell-free nucleic acids.

Authors:  Taisuke Imamura; Shuhei Komatsu; Daisuke Ichikawa; Tsutomu Kawaguchi; Mahito Miyamae; Wataru Okajima; Takuma Ohashi; Tomohiro Arita; Hirotaka Konishi; Atsushi Shiozaki; Ryo Morimura; Hisashi Ikoma; Kazuma Okamoto; Eigo Otsuji
Journal:  World J Gastroenterol       Date:  2016-07-07       Impact factor: 5.742

6.  A novel terpenoid class for prevention and treatment of KRAS-driven cancers: Comprehensive analysis using in situ, in vitro, and in vivo model systems.

Authors:  Arsheed A Ganaie; Hifzur R Siddique; Ishfaq A Sheikh; Aijaz Parray; Lei Wang; Jayanth Panyam; Peter W Villalta; Yibin Deng; Badrinath R Konety; Mohammad Saleem
Journal:  Mol Carcinog       Date:  2020-04-15       Impact factor: 4.784

7.  Pharmacodynamic separation of gemcitabine and erlotinib in locally advanced or metastatic pancreatic cancer: therapeutic and biomarker results.

Authors:  Thomas Semrad; Afsaneh Barzi; Heinz-Josef Lenz; Irene M Hutchins; Edward J Kim; I-Yeh Gong; Michael Tanaka; Laurel Beckett; William Holland; Rebekah A Burich; Leslie Snyder-Solis; Philip Mack; Primo N Lara
Journal:  Int J Clin Oncol       Date:  2014-08-05       Impact factor: 3.402

8.  Interleukin-6 is required for pancreatic cancer progression by promoting MAPK signaling activation and oxidative stress resistance.

Authors:  Yaqing Zhang; Wei Yan; Meredith A Collins; Filip Bednar; Sabita Rakshit; Bruce R Zetter; Ben Z Stanger; Ivy Chung; Andrew D Rhim; Marina Pasca di Magliano
Journal:  Cancer Res       Date:  2013-10-04       Impact factor: 12.701

9.  KRAS mutation: comparison of testing methods and tissue sampling techniques in colon cancer.

Authors:  Wilbur A Franklin; Jerry Haney; Michio Sugita; Lynne Bemis; Antonio Jimeno; Wells A Messersmith
Journal:  J Mol Diagn       Date:  2009-12-10       Impact factor: 5.568

10.  Pancreatic adenocarcinomas frequently show p53 gene mutations.

Authors:  A Scarpa; P Capelli; K Mukai; G Zamboni; T Oda; C Iacono; S Hirohashi
Journal:  Am J Pathol       Date:  1993-05       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.